MARKI-MICROWAVE
27.9.2022 08:51:34 CEST | Business Wire | Press release
European Microwave Week – Marki Microwave®, innovator in the radio frequency and microwave industry for over 30 years, today announced the expansion of its millimeter wave (mmWave) portfolio with a series of leading-edge mixers featuring integrated local oscillator (LO) drivers. Ideal for space constrained applications requiring wide bandwidths and operation at mmWave frequencies, the integrated drive mixers reduce size, weight, power and cost (SWaP-C) while simplifying overall integration of the LO path for ease of use and optimized performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005833/en/
Marki Microwave's versatile, broadband double balanced mixers feature an integrated LO driver amplifier, which allows for operation with LO powers as low as -6 dBm. (Graphic: Business Wire)
“For customers needing to realize the best performance in a small footprint with reduced design effort, our latest integrated drive mixers are game changers,” said Duncan Pilgrim, vice president of sales and marketing at Marki Microwave. “The designs deliver high performance across a wide bandwidth with reduced drive requirements, promising ease of use in a traditionally complex design space.”
The MM1A-0832HPSM, MM1A-1040HPSM and MM1A-1855HPSM are versatile, broadband double balanced mixers featuring an integrated LO driver amplifier, which allows for operation with LO powers as low as -6 dBm. Unlike traditional industry solutions using discrete packages, which often suffer from subpar performance, Marki Microwave’s co-packaging utilizes optimal die technology for the amplifier and mixer functions. The new technique eliminates the need for a separate amplifier and mixer interface, minimizing design costs without sacrificing performance across the operating bandwidth. The new integrated drive mixers’ exceptional conversion loss and linearity combined with their compact footprint make the parts an ideal solution for high performance test and measurement, aerospace and defense, telecom infrastructure and satellite designs.
Availability
The MM1A-0832HPSM, MM1A-1040HPSM and MM1A-1855HPSM will be available in October in 3 x 4.6 mm QFN packages. Specifications subject to change without notice. For samples and sales information, contact sales@markimicrowave.com.
About Marki Microwave
For over 30 years, Marki Microwave has solved its customers’ most complex problems by creating a robust portfolio of performance shattering RF and microwave components. Founded in 1991 with the goal to develop the best mixers in the industry, Marki Microwave now has the highest performance portfolio of broadband mixers, spanning frequencies from 10 MHz to 130 GHz+ in die, surface mount and connectorized form factors. Today, Marki Microwave is a single source for high performance, broadband microwave products, supporting multiple form factors including die, surface mount and connectorized solutions for the entire RF block diagram. As demands from RF and microwave markets continue to evolve and the supply base consolidates, Marki Microwave remains dedicated to building beyond performance barriers, expanding its catalog and empowering the industry to build next-generation systems. For more information, visit www.markimicrowave.com.
© 2022. Marki Microwave, Inc. All Rights Reserved. Marki Microwave, the Marki logo, and T3 Mixer are trademarks or registered trademarks of Marki Microwave, Inc., in the U.S. and other countries. All other trademarks are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005833/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom